UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis | Index Medicus
Journal Article
Nature medicine, ISSN 1078-8956, 09/2019, Volume 25, Issue 9, pp. 1422 - 1427
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Mitogen-Activated Protein Kinase Kinases - genetics | Humans | Oximes - administration & dosage | Imidazoles - administration & dosage | Cell-Free Nucleic Acids - drug effects | Male | Cell-Free Nucleic Acids - genetics | Indazoles - administration & dosage | Molecular Targeted Therapy | Young Adult | Pyridones - administration & dosage | Benzamides - administration & dosage | Heterografts | Neoplasms - genetics | Adult | Female | Child | Pyrimidines - administration & dosage | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Clinical Trials as Topic | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Pyrazoles - administration & dosage | Animals | MAP Kinase Signaling System - drug effects | Oncogene Proteins, Fusion - genetics | Adolescent | Receptor, trkA - genetics | Cell Proliferation - drug effects | Mice | Pyrimidinones - administration & dosage | Neoplasms - pathology | Drug Resistance, Neoplasm - drug effects | MAP kinase | Kinases | Disease control | Patients | Convergence | Alterations | Addiction | Protein kinase | Delay time | Solid tumors | Inhibition | Mutation | Target acquisition | Tumors | Cancer | Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1631 - 1639
Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Pyridones - administration & dosage | Time Factors | Melanoma - genetics | Skin Neoplasms - mortality | Protein Kinase Inhibitors - pharmacokinetics | Skin Neoplasms - pathology | Double-Blind Method | Drug Administration Schedule | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Melanoma - secondary | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | trametinib | durable outcomes | metastatic | melanoma | BRAF | Original | dabrafenib
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1893 - 1901
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Tumors of the skin and soft tissue. Premalignant lesions | Neurology | General aspects | Tumors of the nervous system. Phacomatoses | Dermatology | Biological and medical sciences | Medical sciences | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 12/2018, Volume 36, Issue 35, pp. 3441 - 3449
Journal Article
The oncologist (Dayton, Ohio), ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | Life Sciences & Biomedicine | Oncology | Science & Technology | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Index Medicus | Melanoma and Cutaneous Malignancies
Journal Article
Future oncology (London, England), ISSN 1479-6694, 09/2019, Volume 15, Issue 25, pp. 2933 - 2942
Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Molecular Targeted Therapy | Pyridones - administration & dosage | Vemurafenib - administration & dosage | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Melanoma - genetics | Immunotherapy | Female | Ipilimumab - administration & dosage | Piperidines - administration & dosage | Treatment Outcome | Melanoma - pathology | CTLA-4 Antigen - immunology | Mutation - genetics | Disease-Free Survival | Azetidines - administration & dosage | Melanoma - immunology | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyrimidinones - administration & dosage | Programmed Cell Death 1 Receptor - immunology | CTLA-4 Antigen - antagonists & inhibitors | Nivolumab - administration & dosage
Journal Article
Blood, ISSN 0006-4971, 09/2017, Volume 130, Issue 11, pp. 1377 - 1380
Life Sciences & Biomedicine | Hematology | Science & Technology | Erdheim-Chester Disease - diagnostic imaging | Follow-Up Studies | Humans | Oximes - administration & dosage | Imidazoles - administration & dosage | Oximes - therapeutic use | Molecular Targeted Therapy | Indoles - administration & dosage | Multicenter Studies as Topic | Registries | Retrospective Studies | Imidazoles - therapeutic use | France | Erdheim-Chester Disease - genetics | Piperidines - administration & dosage | Drug Administration Schedule | Treatment Outcome | Positron Emission Tomography Computed Tomography | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Erdheim-Chester Disease - drug therapy | Azetidines - administration & dosage | Azetidines - therapeutic use | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Indoles - therapeutic use | Sulfonamides - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Fertility and sterility, ISSN 0015-0282, 2013, Volume 99, Issue 5, pp. 1305 - 1310
Internal Medicine | Obstetrics and Gynecology | combined contraception | follicle development | Antimüllerian hormone | FSH | inhibin B | Life Sciences & Biomedicine | Obstetrics & Gynecology | Reproductive Biology | Science & Technology | Norgestrel - administration & dosage | Prospective Studies | Humans | Contraceptive Devices, Female | Oximes - administration & dosage | Administration, Cutaneous | Follicle Stimulating Hormone, Human - blood | Young Adult | Desogestrel - administration & dosage | Ovarian Follicle - drug effects | Adult | Female | Norgestrel - analogs & derivatives | Ethinyl Estradiol - administration & dosage | Anti-Mullerian Hormone - blood | Contraceptives, Oral, Combined - administration & dosage | Estrogens - administration & dosage | Pituitary Gland - drug effects | Oral contraceptives | Usage | Hormones | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 1, pp. 30 - 39
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article